Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.
The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras mutation. The approval covers the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy. Sotorasib is the first KRAS-targeted therapy to be approved after nearly four decades of research, the company said. The approval is based on the overall response rate (ORR) and duration of response (DoR). Lumakras demonstrated an ORR of 36% in the trial, with 81% of patients achieving disease control. The median DoR was ten months. Continued approval for the indication depends on clinical benefit in a confirmatory trial(s). Amgen has partnered with Guardant Health Inc (NASDAQ: GH) and Qiagen NV (NYSE: QGEN) to develop blood- and tissue-based companion diagnostics, respectively, for Lumakras. Related content: Benzinga's Full FDA Calendar Price Action: AMGN shares are up 0.40% at $236.26 during the market session on the last check Friday. See more from BenzingaClick here for options trades from BenzingaSorrento Reports Encouraging Data From Sofusa-Administered Enbrel In Rheumatoid ArthritisSupreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.